MUSC Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, 25 Courtenay Dr., Charleston, SC, 29425, USA.
Division of Cardiology, Medical University of South Carolina, Charleston, USA.
Dig Dis Sci. 2024 Aug;69(8):3061-3068. doi: 10.1007/s10620-024-08438-1. Epub 2024 May 23.
Patients with cirrhosis are at risk for cardiac complications such as heart failure, particularly heart failure with preserved ejection fraction (HFpEF) due to left ventricular diastolic dysfunction (LVDD). The H2FPEF score is a predictive model used to identify patients with HFpEF. Our primary aim was to assess the H2FPEF score in patients with cirrhosis and determine its potential to identify patients at risk for heart failure after liver transplant.
This was a cohort study of patients undergoing liver transplant for cirrhosis from January 2010 and October 2018 who had a pre-transplant transthoracic echocardiogram.
166 cirrhosis subjects were included in the study. The majority were men (65%) and Caucasian (85%); NASH was the most common cause of cirrhosis (41%) followed by alcohol (34%). The median H2FPEF score was 2.0 (1.0-4.0). Patients with NASH cirrhosis had higher H2FPEF scores (3.22, 2.79-3.64) than those with alcohol induced cirrhosis (1.89, 1.5-2.29, p < 0.001) and other causes of cirrhosis (1.73, 1.28-2.18, p < 0.001). All subjects with a H2FPEF score > 6 had NASH cirrhosis. There was no association between the H2FPEF scores and measures of severity of liver disease (bilirubin, INR, or MELD score). Patients with heart failure after liver transplant had higher H2FPEF scores than those without heart failure (4.0, 3.1-4.9 vs. 2.3, 2.1-2.6, respectively; p = 0.015), but the score did not predict post-transplant mortality.
H2FPEF scores are higher in cirrhosis patients with NASH and appear to be associated with post-transplant heart failure, but not death.
肝硬化患者存在心脏并发症的风险,例如心力衰竭,尤其是由于左心室舒张功能障碍(LVDD)导致的射血分数保留型心力衰竭(HFpEF)。H2FPEF 评分是一种用于识别 HFpEF 患者的预测模型。我们的主要目的是评估肝硬化患者的 H2FPEF 评分,并确定其在肝移植后识别心力衰竭风险患者的潜力。
这是一项队列研究,纳入了 2010 年 1 月至 2018 年 10 月期间因肝硬化接受肝移植的患者,这些患者在肝移植前进行了经胸超声心动图检查。
研究纳入了 166 例肝硬化患者。大多数为男性(65%)和白种人(85%);非酒精性脂肪性肝炎(NASH)是肝硬化最常见的病因(41%),其次是酒精(34%)。H2FPEF 评分中位数为 2.0(1.0-4.0)。NASH 肝硬化患者的 H2FPEF 评分较高(3.22,2.79-3.64),高于酒精性肝硬化患者(1.89,1.5-2.29,p<0.001)和其他病因肝硬化患者(1.73,1.28-2.18,p<0.001)。所有 H2FPEF 评分>6 的患者均为 NASH 肝硬化。H2FPEF 评分与肝脏疾病严重程度的测量指标(胆红素、INR 或 MELD 评分)之间无相关性。肝移植后发生心力衰竭的患者 H2FPEF 评分高于未发生心力衰竭的患者(分别为 4.0,3.1-4.9 与 2.3,2.1-2.6;p=0.015),但该评分不能预测移植后死亡率。
NASH 肝硬化患者的 H2FPEF 评分较高,似乎与移植后心力衰竭有关,但与死亡无关。